X0306 4 2014-12-19 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001230708 STAAB THOMAS R II 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 Senior Vice President and CFO Emp. Stock Option (Right to Buy) 5.45 2014-12-19 4 A 0 17000 0 A 2014-12-19 2023-08-08 Common Stock 17000 17000 D On December 19, 2014, the U.S. Food and Drug Administration (FDA) approved RAPIVAB (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on December 19, 2014. /s/ Alane P. Barnes, by power of attorney 2014-12-23